Member area login

You don't have or don't remember the password!
Click Here

Editor-in-chief
Maria Stella Graziani

Deputy Director
Martina Zaninotto

Associate Editors
Ferruccio Ceriotti
Davide Giavarina
Bruna Lo Sasso
Giampaolo Merlini
Martina Montagnana
Andrea Mosca
Paola Pezzati
Rossella Tomaiuolo
Matteo Vidali

EIC Assistant
Francesco Busardò

International Advisory Board Khosrow Adeli Canada
Sergio Bernardini Italy
Marcello Ciaccio Italy
Eleftherios Diamandis Canada
Philippe Gillery France
Kjell Grankvist Sweden
Hans Jacobs The Netherlands
Eric Kilpatrick UK
Magdalena Krintus Poland
Giuseppe Lippi Italy
Mario Plebani Italy
Sverre Sandberg Norway
Ana-Maria Simundic Croatia
Tommaso Trenti Italy
Cas Weykamp The Netherlands
Maria Willrich USA
Paul Yip Canada

Publisher
Biomedia srl
Via L. Temolo 4, 20126 Milano

Responsible Editor
Giuseppe Agosta

Editorial Secretary
Chiara Riva
Biomedia srl
Via L. Temolo 4, 20126 Milano
Tel. 0245498282
email: biochimica.clinica@sibioc.it

--------------------

ISSN print: 0393 – 0564
ISSN digital: 0392- 7091

BC: Articoli scritti da P. Uva

Il microRNA-135b nella caratterizzazione molecolare del carcinoma della mammella “triplo negativo”
miRNA-135b in molecular characterization of triple-negative breast cancer (TNBC)
G. Pira \| L. Murgia \| F. Sanges \| P. Uva \| P. Cossu-Rocca \| F. Loi \| S. Orrù \| M.R. Muroni \| C. Carru \| A. Angius \| M.R. De Miglio \|
<p>TNBC accounts for 12-24% of all mammary cancers (BC). Its clinical and genetic heterogeneity and the lack of unambiguous molecular targets contribute to the scarcity of therapeutic options for this BC variant. Recently, the BC molecular biology has entered in the era of microRNAs (miRNA), a class of small highly conserved regulatory endogenous non-coding RNAs, which control complicated signaling pathways, governing cell cycle, proliferation, differentiation, apoptosis, etc., and whose deregulation contributes to the tumour development. Our goal was to improve the knowledge of TNBC biology analyzing the miRNA expression profile and to identify new potential prognostic and predictive biomarkers. We conducted a human miRNome analysis by TaqMan Low Density Array comparing different TNBC subtypes, defined by immunohistochemical basal markers, such as epidermal growth factor receptor and cytokeratin 5/6. Quantitative reverse transcription polymerase chain reaction confirmed differential expression of miRNA. We identified a single miRNA signature given by miR-135b expression levels, which allowed the distinction of TNBC with and without basal-like phenotype. Our study sheds light on the molecular complexity of TNBC and shows for the first time that miR-135b expression is strictly related to TNBC basal-like molecular subtype, acting as an oncogene in the tumor pathogenesis.</p>
Biochimica Clinica ; 41(3) 239-244 Contributi scientifici - Scientific papers